Literature DB >> 18639457

Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study.

Karim Wahbi1, Christophe Meune, El Hadi Hamouda, Tania Stojkovic, Pascal Laforêt, Henri Marc Bécane, Bruno Eymard, Denis Duboc.   

Abstract

Mutations in the FKRP gene may be associated with cardiac involvement. The aim of our study was to assess myocardial involvement in patients with LGMD2I, using physical examination, echocardiography, resting and 24-h ambulatory electrocardiogram and cardiac magnetic resonance imaging, with particular attention to the detection of myocardial morphologic abnormalities. Patients were compared to matched controls. Twenty-three patients were enrolled (men 10--women 13; 32.3+/-9.5 years). Twenty-two had the C826A gene mutation (homozygous 12, heterozygous 10). Nine patients had severe muscle alterations, 10 had milder muscle involvement and 4 had isolated exertional myoglobinuria. When compared to controls, LGMD2I patients had reduced left ventricular ejection fraction (50.8+/-13.9 versus 66.6+/-3.8%, p<0.0001). Sixty percent of patients had reduced left ventricular ejection fraction, including 8% with severe reduced left ventricular ejection fraction <30%. None had significant arrhythmia. Gene mutation and the severity of the muscle disease were not predictive of cardiac involvement. Cardiac magnetic resonance imaging displayed a high prevalence of myocardial functional abnormalities, fatty replacement and fibrosis, among the 13 patients investigated. Reduced contractility and cardiac magnetic resonance imaging morphological abnormalities are highly prevalent in LGMD2I patients suggesting that all patients should be referred for cardiac evaluation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639457     DOI: 10.1016/j.nmd.2008.06.365

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  21 in total

1.  The proteoglycan-dystrophin complex in genetic cardiomyopathies--lessons from three siblings with limb-girdle muscular dystrophy-2I (LGMD-2I).

Authors:  Ali Yilmaz; Hans-Jürgen Gdynia; Matthias Ponfick; Albert C Ludolph; Sabine Rösch; Udo Sechtem
Journal:  Clin Res Cardiol       Date:  2011-02-11       Impact factor: 5.460

2.  A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.

Authors:  Peter R Serafini; Michael J Feyder; Rylie M Hightower; Daniela Garcia-Perez; Natássia M Vieira; Angela Lek; Devin E Gibbs; Omar Moukha-Chafiq; Corinne E Augelli-Szafran; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel; Matthew S Alexander
Journal:  JCI Insight       Date:  2018-09-20

3.  Obstetric management of a woman with limb-girdle muscular dystrophy type 2i and dilated cardiomyopathy.

Authors:  Alexandra von Guionneau; Charlotte Burford; Sophia Stone
Journal:  Obstet Med       Date:  2018-12-11

4.  AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.

Authors:  Evelyne Gicquel; Natacha Maizonnier; Steven J Foltz; William J Martin; Nathalie Bourg; Fedor Svinartchouk; Karine Charton; Aaron M Beedle; Isabelle Richard
Journal:  Hum Mol Genet       Date:  2017-05-15       Impact factor: 6.150

5.  Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery.

Authors:  Chunping Qiao; Chi-Hsien Wang; Chunxia Zhao; Peijuan Lu; Hiroyuki Awano; Bin Xiao; Jianbin Li; Zhenhua Yuan; Yi Dai; Carrie Bette Martin; Juan Li; Qilong Lu; Xiao Xiao
Journal:  Mol Ther       Date:  2014-07-22       Impact factor: 11.454

6.  Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function.

Authors:  Zhyldyz Kabaeva; Kailyn E Meekhof; Daniel E Michele
Journal:  Hum Mol Genet       Date:  2011-05-30       Impact factor: 6.150

Review 7.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.

Authors:  D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil
Journal:  J Inherit Metab Dis       Date:  2017-07-19       Impact factor: 4.982

8.  Cardiac pathology exceeds skeletal muscle pathology in two cases of limb-girdle muscular dystrophy type 2I.

Authors:  Marta Margeta; Anne M Connolly; Thomas L Winder; Alan Pestronk; Steven A Moore
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

9.  Further evidence of Fukutin mutations as a cause of childhood onset limb-girdle muscular dystrophy without mental retardation.

Authors:  Rebecca L Puckett; Steven A Moore; Thomas L Winder; Tobias Willer; Stephen G Romansky; Kelly King Covault; Kevin P Campbell; Jose E Abdenur
Journal:  Neuromuscul Disord       Date:  2009-04-01       Impact factor: 4.296

Review 10.  Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.

Authors:  Justin R Fallon; Elizabeth M McNally
Journal:  Matrix Biol       Date:  2018-02-23       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.